Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06900998 · ClinicalTrials.gov registry record · Phase 2
Pilot Study: Effects of Nimodipine on Alcohol Drinking
A Phase 2 study, sponsored by Yale University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT06900998: Clinical Trial Phase 2 study, sponsored by Yale University.
NCT06900998 is a Phase 2 study that has not yet begun recruiting, run by Yale University. The registered enrollment target is 5 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06900998, a Phase 2 study, has not yet begun recruiting, sponsored by Yale University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipine 90 mg/dose every six hours during an 18-hour period prior to the ADP to allow for the limited central nervous system bioavailability of this drug. Electroencephalogram (EEG) data will be collected before the first dose and after the last dose of nimodipine. Adverse events will be closely monitored during this period. During the ADP session participants will receive a priming dose of alcohol followed by a one-hour monitoring period. This will be followed by three one-hour self-administration periods; during each hour, participants will be able to choose between drinking up to four drinks or receive the monetary equivalents of these drinks (total of 12 drinks over three hours).
Primary Outcome
Total number of drinks (out of 12) that were consumed during the alcohol drinking paradigm (ADP) session.
Interventions
- DRUG Nimodipine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2026-09-01 |
| Est. Completion | 2032-06-30 |
| Phase | Phase 2 |
What is known before NCT06900998 opens enrollment
NCT06900998 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (96% lower).
The record links to 0 conditions, and to 1 intervention - of which Nimodipine is the first listed.
NCT06900998 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06900998 about?
NCT06900998 is a clinical study titled "Pilot Study: Effects of Nimodipine on Alcohol Drinking". This is an open label trial aiming to recruit 5 non-treatment seeking adults with Alcohol Use Disorder. All will participate in an alcohol drinking paradigm (ADP) lab session at the Hospital Research Unit (HRU) at Yale-New Haven Hospital (YNHH). Participants will stay overnight and receive nimodipin...
What is the current status of trial NCT06900998?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2026-09-01. Estimated completion is 2032-06-30.
What interventions are being tested in trial NCT06900998?
The interventions under investigation include: Nimodipine (DRUG).
Who is sponsoring clinical trial NCT06900998?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06900998's enrollment target sits among peer trials
5 2000th of 2000 the lowest of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI